BSELink Pharma Chem LtdHighNeutral
Announced Tue, 27 May · 18:13 IST

Outcome of Board Meeting held on 27th May, 2025.

Revenue DeclinePat NegativeResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The Board approved audited financial results for the quarter and year ended March 31, 2025. Revenue from operations fell about 15% to Rs 2,543.34 lakhs (FY24: Rs 2,989.77 lakhs). The company reported a net loss of Rs 102.73 lakhs for FY25, though the loss narrowed from Rs 136.29 lakhs in FY24. Q4 FY25 revenue was Rs 644.66 lakhs with a loss of Rs 35.02 lakhs, against a profit of Rs 26 lakhs in Q4 FY24. EPS was negative Rs 2.31 (FY24: negative Rs 3.07). Operating cash flow improved sharply to Rs 268.59 lakhs from a negative Rs 2.80 lakhs last year. Statutory auditor CNK & Associates LLP issued an unmodified opinion. The Board also re-appointed Secretarial Auditor (Vijay Bhatt & Co.), Internal Auditor (Dipak Rajpara & Co.), and Cost Auditor (Y.S. Thakar & Co.) for FY26.

Likely market impact

Continued losses and a revenue decline are concerning for shareholders, but the narrower loss, improved operating cash flow, and clean audit offer some comfort. The stock may face pressure given the weak topline and persistent bottom-line losses.